Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases Encouraging safety and cellular immune response data as well as a promising reactogenicity profile warrant further evaluation of OVX836 in Phase 2a study Lyon, France – December 2nd, 2021 – Osivax, a biopharmaceutical company focused …
Archives de l’auteur : Marianne Duparc
ISIRV-WHO
Virtual – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present the last clinical results of OVX836 as part of a poster entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».
A Day @Bioaster
Lyon – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a general update on OVX836 as part of a presentation entitled « the development of a universal influenza vaccine: a precision approach to control diversity – NP as an attractive target for T cell based universal flu vaccine. »
Vaccine Summit 2021
Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».
Global Conference on Vaccines Research and Development
Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».
2020 Vaccinology Club of French Society for Immunology
Lille – Oral PresentationFlorence Nicolas, Director of R&D and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza vaccine candidate: Short-term results of the Phase 1 clinical trial ».
5th international Conference on Vaccines R&D
Boston – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ».
World Vaccine Congress Europe
Barcelona – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ».
OPTIONS X
Singapore – Oral Presentations and PostersAlexandre Le Vert to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ». Delphine Guyon-Gellin and Nicolas Noulin (hVIVO) to present « Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human …
Influenza Vaccines for the World
Edinburgh – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide preclinical results of OVX836 as part of a presentation entitled « OVX836 protects mice in lethal challenges with multiples strains of influenza A viruses ».